Exelixis, Inc. To Release Third Quarter 2014 Financial Results On Tuesday, November 4, 2014
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2014 financial results will be released on Tuesday, November 4, 2014 after the markets close. At 5:00 p.m. EST / 2:00 p.m. PST, Exelixis management will host a conference call to discuss the Company's financial results for the third quarter 2014 and provide a general business update. The conference call will be accessible via the Internet from the Company’s website.
To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under Investors & Media. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 1-866-270-6057 (domestic) or 1-617-213-8891 (international) and provide the conference call passcode 72954080 to join by phone. A telephone replay will be available until 11:59 p.m. EST on December 4, 2014. Access numbers for the telephone replay are: 888-286-8010 (domestic) and 617-801-6888 (international); the passcode is 91709998. A webcast replay will also be archived on www.exelixis.com for 30 days.
About Exelixis
Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ® (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a highly selective inhibitor of MEK, is being evaluated by Roche and Genentech, Inc. (a member of the Roche Group) in a broad development program under a collaboration with Exelixis. For more information, please visit the company's web site at www.exelixis.com.
Exelixis, the Exelixis logo, and COMETRIQ are registered U.S. trademarks.
Contacts
Exelixis, Inc.
Susan Hubbard, 650-837-8194
Investor Relations and Corporate Communications
shubbard@exelixis.com
Source: Exelixis, Inc.
Help employers find you! Check out all the jobs and post your resume.
To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under Investors & Media. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 1-866-270-6057 (domestic) or 1-617-213-8891 (international) and provide the conference call passcode 72954080 to join by phone. A telephone replay will be available until 11:59 p.m. EST on December 4, 2014. Access numbers for the telephone replay are: 888-286-8010 (domestic) and 617-801-6888 (international); the passcode is 91709998. A webcast replay will also be archived on www.exelixis.com for 30 days.
About Exelixis
Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ® (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a highly selective inhibitor of MEK, is being evaluated by Roche and Genentech, Inc. (a member of the Roche Group) in a broad development program under a collaboration with Exelixis. For more information, please visit the company's web site at www.exelixis.com.
Exelixis, the Exelixis logo, and COMETRIQ are registered U.S. trademarks.
Contacts
Exelixis, Inc.
Susan Hubbard, 650-837-8194
Investor Relations and Corporate Communications
shubbard@exelixis.com
Source: Exelixis, Inc.
Help employers find you! Check out all the jobs and post your resume.